Sirolimus-Eluting Versus Paclitaxel-Eluting Stent Implantation for the Percutaneous Treatment of Left Main Coronary Artery Disease
A Combined RESEARCH and T-SEARCH Long-Term Analysis
Marco Valgimigli, MD,
Patrizia Malagutti, MD,
Jiro Aoki, MD,
Héctor M. Garcia-Garcia, MD,
Gaston A. Rodriguez Granillo, MD,
Carlos A.G. van Mieghem, MD,
Jurgen M. Ligthart, BSc,
Andrew T.L. Ong, MBBS, FRACP,
George Sianos, MD, PhD,
Evelyn Regar, MD, PhD,
Ron T. Van Domburg, PhD,
Pim De Feyter, MD, PhD,
Peter de Jaegere, MD, PhD and
Patrick W. Serruys, MD, PhD*
Erasmus Medical Center, Thoraxcenter, Rotterdam, the Netherlands.
View larger version (13K):
[in a new window]
|
Figure 1 Adverse events in patients treated with sirolimus-eluting stent (SES group) and in patients treated exclusively with paclitaxel-eluting stent implantation (PES group). (A) Cumulative risk of major adverse events (MACE); (B) death or myocardial infarction (MI); and (C) target vessel revascularization (TVR). CI = confidence interval.
|
|
|
